Trial Profile
Phase Ib Trial of HER2/Neu Peptide (E75) Vaccine in Breast Cancer Patients at Risk for Recurrence After Surgical and Medical Therapies.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Nelipepimut-S (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Oct 2013 Results have been presented at the American College of Surgeons Clinical Congress 2013 according to a Galena Biopharma media release. Results were also summarised in the media release.
- 05 Jun 2013 Results of this trial and SN 34 [Profile 700020466] presented at American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting, according to a Galena Biopharma media release.
- 12 Mar 2013 Data has been presented at the 27th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), according to a Galena Biopharma media release.